4.6 Review

Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation

期刊

SEMINARS IN CANCER BIOLOGY
卷 43, 期 -, 页码 74-89

出版社

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcancer.2017.03.001

关键词

Acidity; Immunity; Cancer; Hypoxia; Lactate; pH; Glycolysis; Tumor microenvironment; Myeloid-derived suppressor cells; Regulatory T cells; Immunotherapy; Immune checkpoints; Therapeutic antibodies; Immunosurveillance

类别

资金

  1. Italian Association for Cancer Research (AIRC) [IG 14285, IG 15192, IG 15359, 5x1000, 12161]
  2. Italian Ministry of Health [GR-2011-02351400, 152/RF-2009-1538005, 52/RF-2010-2312620]

向作者/读者索取更多资源

The link between cancer metabolism and immunosuppression, inflammation and immune escape has generated major interest in investigating the effects of low pH on tumor immunity. Indeed, microenvironmental acidity may differentially impact on diverse components of tumor immune surveillance, eventually contributing to immune escape and cancer progression. Although the molecular pathways underlying acidity-related immune dysfunctions are just emerging, initial evidence indicates that antitumor effectors such as T and NK cells tend to lose their function and undergo a state of mostly reversible anergy followed by apoptosis, when exposed to low pH environment. At opposite, immunosuppressive components such as myeloid cells and regulatory T cells are engaged by tumor acidity to sustain tumor growth while blocking antitumor immune responses. Local acidity could also profoundly influence bioactivity and distribution of antibodies, thus potentially interfering with the clinical efficacy of therapeutic antibodies including immune checkpoint inhibitors. Hence tumor acidity is a central regulator of cancer immunity that orchestrates both local and systemic immunosuppression and that may offer a broad panel of therapeutic targets. This review outlines the fundamental pathways of acidity-driven immune dysfunctions and sheds light on the potential strategies that could be envisaged to potentiate immune-mediated tumor control in cancer patients. (C) 2017 The Authors. Published by Elsevier Ltd.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据